Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shampa Das

Showing results (41-50 of 51) with videos related to

Pageof 6
Sort By:
The Journal of Antimicrobial Chemotherapy|March 24, 2026
The magnitude of the pharmacodynamic index for NOSO-502: pathogen clearance, emergence of resistance and human dose predictionsSanne van den Berg, Marie Attwood, Pippa Griffin, et al.
Antimicrobial Agents and Chemotherapy|August 10, 2016
Phase I Study Assessing the Pharmacokinetic Profile, Safety, and Tolerability of a Single Dose of Ceftazidime-Avibactam in Hospitalized Pediatric PatientsJohn S Bradley, Jon Armstrong, Antonio Arrieta, et al.
The Journal of Antimicrobial Chemotherapy|February 16, 2022
Flomoxef and fosfomycin in combination for the treatment of neonatal sepsis in the setting of highly prevalent antimicrobial resistanceChristopher A Darlow, Nicola Farrington, Adam Johnson, et al.
The Journal of Antimicrobial Chemotherapy|September 30, 2022
Assessment of flomoxef combined with amikacin in a hollow-fibre infection model for the treatment of neonatal sepsis in low- and middle-income healthcare settingsChristopher A Darlow, Laura McEntee, Adam Johnson, et al.
Antimicrobial Agents and Chemotherapy|October 20, 2020
Intrapulmonary Pharmacokinetics of Cefepime and Enmetazobactam in Healthy Volunteers: Towards New Treatments for Nosocomial PneumoniaShampa Das, Richard Fitzgerald, Asad Ullah, et al.
The Journal of Antimicrobial Chemotherapy|October 16, 2024
Population pharmacokinetics/pharmacodynamics of minocycline plus rifampicin in patients with complicated skin and skin structure infections caused by MRSASonia Luque Pardos, William Hope, Antigone Kotsaki, et al.
Antimicrobial Agents and Chemotherapy|May 11, 2021
Amikacin Combined with Fosfomycin for Treatment of Neonatal Sepsis in the Setting of Highly Prevalent Antimicrobial ResistanceChristopher A Darlow, Fernando Docobo-Perez, Nicola Farrington, et al.
Nature Communications|September 18, 2025
The bactericidal FabI inhibitor Debio 1453 clears antibiotic-resistant Neisseria gonorrhoeae infection in vivoVincent Gerusz, Pierre Regenass, Quentin Rousseau, et al.
Nature Communications|September 18, 2024
BWC0977, a broad-spectrum antibacterial clinical candidate to treat multidrug resistant infectionsShahul Hameed P, Harish Kotakonda, Sreevalli Sharma, et al.
The Lancet. Infectious Diseases|October 3, 2024
Estimates of the burden of human rabies deaths and animal bites in India, 2022-23: a community-based cross-sectional survey and probability decision-tree modelling studyJeromie Wesley Vivian Thangaraj, Navaneeth S Krishna, Shanmugasundaram Devika, et al.
Pageof 6

Showing results (41-50 of 51) with videos related to

Sort By:
Pageof 6
The Journal of Antimicrobial Chemotherapy|March 24, 2026
The magnitude of the pharmacodynamic index for NOSO-502: pathogen clearance, emergence of resistance and human dose predictionsSanne van den Berg, Marie Attwood, Pippa Griffin, et al.
Antimicrobial Agents and Chemotherapy|August 10, 2016
Phase I Study Assessing the Pharmacokinetic Profile, Safety, and Tolerability of a Single Dose of Ceftazidime-Avibactam in Hospitalized Pediatric PatientsJohn S Bradley, Jon Armstrong, Antonio Arrieta, et al.
The Journal of Antimicrobial Chemotherapy|February 16, 2022
Flomoxef and fosfomycin in combination for the treatment of neonatal sepsis in the setting of highly prevalent antimicrobial resistanceChristopher A Darlow, Nicola Farrington, Adam Johnson, et al.
The Journal of Antimicrobial Chemotherapy|September 30, 2022
Assessment of flomoxef combined with amikacin in a hollow-fibre infection model for the treatment of neonatal sepsis in low- and middle-income healthcare settingsChristopher A Darlow, Laura McEntee, Adam Johnson, et al.
Antimicrobial Agents and Chemotherapy|October 20, 2020
Intrapulmonary Pharmacokinetics of Cefepime and Enmetazobactam in Healthy Volunteers: Towards New Treatments for Nosocomial PneumoniaShampa Das, Richard Fitzgerald, Asad Ullah, et al.
The Journal of Antimicrobial Chemotherapy|October 16, 2024
Population pharmacokinetics/pharmacodynamics of minocycline plus rifampicin in patients with complicated skin and skin structure infections caused by MRSASonia Luque Pardos, William Hope, Antigone Kotsaki, et al.
Antimicrobial Agents and Chemotherapy|May 11, 2021
Amikacin Combined with Fosfomycin for Treatment of Neonatal Sepsis in the Setting of Highly Prevalent Antimicrobial ResistanceChristopher A Darlow, Fernando Docobo-Perez, Nicola Farrington, et al.
Nature Communications|September 18, 2025
The bactericidal FabI inhibitor Debio 1453 clears antibiotic-resistant Neisseria gonorrhoeae infection in vivoVincent Gerusz, Pierre Regenass, Quentin Rousseau, et al.
Nature Communications|September 18, 2024
BWC0977, a broad-spectrum antibacterial clinical candidate to treat multidrug resistant infectionsShahul Hameed P, Harish Kotakonda, Sreevalli Sharma, et al.
The Lancet. Infectious Diseases|October 3, 2024
Estimates of the burden of human rabies deaths and animal bites in India, 2022-23: a community-based cross-sectional survey and probability decision-tree modelling studyJeromie Wesley Vivian Thangaraj, Navaneeth S Krishna, Shanmugasundaram Devika, et al.
Pageof 6